Read by QxMD icon Read

Ankylosing spondyloarthritis

Gothic P Thomas, Dana Willner, Philip C Robinson, Adrian Cortes, Ran Duan, Martin Rudwaleit, Nurullah Akkoc, Jurgen Braun, Chung-Tei Chou, Walter P Maksymowych, Salih Ozgocmen, Euthalia Roussou, Joachim Sieper, Rafael Valle-Oñate, Desiree van der Heijde, James Wei, Paul Leo, Matthew A Brown
OBJECTIVES: Spondyloarthritis (SpA) is often diagnosed late in the course of the disease and improved methods for early diagnosis are required. We have tested the ability of genetic profiling to diagnose axial SpA (axSpA) as a whole group, or ankylosing spondylitis (AS) alone, in a cohort of chronic back pain patients. METHODS: 282 patients were recruited from centres in the United Kingdom, Germany, Taiwan, Canada, Columbia and Turkey as part of the ASAS classification criteria for axSpA study (ASAS cohort)...
October 7, 2016: Clinical and Experimental Rheumatology
Maxime Dougados, Emily Wood, Laure Gossec, Désirée van der Heijde, Isabelle Logeart
OBJECTIVES: To assess symptomatic outcomes associated with flare after discontinuation of non-steroidal anti-inflammatory drugs (NSAIDs) in axial spondyloarthritis (axSpA). METHODS: Patients with NSAID-refractory axSpA discontinued NSAIDs, restarted if symptoms recurred, and self-recorded Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). 75th percentiles were calculated for changes in BASDAI total and components from NSAID discontinuation to resumption...
September 7, 2016: Clinical and Experimental Rheumatology
Joachim Sieper, Tim Holbrook, Christopher M Black, Robert Wood, Xiaohan Hu, Sumesh Kachroo
OBJECTIVES: To assess the impact of non-radiographic axial spondyloarthritis (nr-axSpA) on patients and society based on real-world evidence from the Adelphi nr-axSpA Disease Specific Programme, a cross-sectional survey of rheumatologists and their patients in Germany, France, Spain, Italy and the UK. METHODS: Physicians completed patient record forms for the next two patients consulting with nr-axSpA (diagnosis at the physician's judgement); patients were invited to complete a patient self-completion form...
August 31, 2016: Clinical and Experimental Rheumatology
Chaoqun Yang, Peipei Ding, Qingkai Wang, Long Zhang, Xin Zhang, Jianquan Zhao, Enjie Xu, Na Wang, Jianfeng Chen, Guang Yang, Weiguo Hu, Xuhui Zhou
Ankylosing spondylitis (AS) is a chronic axial spondyloarthritis (SpA) resulting in back pain and progressive spinal ankyloses. Currently, there are no effective therapeutics targeting AS largely due to elusive pathogenesis mechanisms, even as potential candidates such as HLA-B27 autoantigen have been identified. Herein, we employed a proteoglycan (PG)-induced AS mouse model together with clinical specimens, and found that the complement system was substantially activated in the spinal bone marrow, accompanied by a remarkable proportion alteration of neutrophils and macrophage in bone marrow and spleen, and by the significant increase of TGF-β1 in serum...
October 4, 2016: Scientific Reports
R Agca, S C Heslinga, S Rollefstad, M Heslinga, I B McInnes, M J L Peters, T K Kvien, M Dougados, H Radner, F Atzeni, J Primdahl, A Södergren, S Wallberg Jonsson, J van Rompay, C Zabalan, T R Pedersen, L Jacobsson, K de Vlam, M A Gonzalez-Gay, A G Semb, G D Kitas, Y M Smulders, Z Szekanecz, N Sattar, D P M Symmons, M T Nurmohamed
Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommended screening, identification of CVD risk factors and CVD risk management largely based on expert opinion. In view of substantial new evidence, an update was conducted with the aim of producing CVD risk management recommendations for patients with IJD that now incorporates an increasing evidence base...
October 3, 2016: Annals of the Rheumatic Diseases
Melissa N van Tok, Nataliya G Yeremenko, Christine A Teitsma, Barbara E Kream, Véronique L Knaup, Rik J Lories, Dominique L Baeten, Leonie M van Duivenvoorde
INTRODUCTION: Insulin like growth factor (IGF)-I can act on a variety of cells involved in cartilage and bone repair, yet IGF-I has not been studied extensively in the context of inflammatory arthritis. The objective of this study was to investigate whether IGF-I overexpression in the osteoblast lineage could lead to increased reparative or pathological bone formation in rheumatoid arthritis and/or spondyloarthritis respectively. METHODS: Mice overexpressing IGF-I in the osteoblast lineage (Ob-IGF-I+/-) line 324-7 were studied during collagen induced arthritis and in the DBA/1 aging model for ankylosing enthesitis...
2016: PloS One
Martin Rudwaleit, Robert Landewé, Joachim Sieper
No abstract text is available yet for this article.
September 29, 2016: New England Journal of Medicine
Corrado Campochiaro, Pier F Caruso
No abstract text is available yet for this article.
September 29, 2016: New England Journal of Medicine
(no author information available yet)
No abstract text is available yet for this article.
September 29, 2016: New England Journal of Medicine
Stéphanie Fabre, Anna Molto, Sabrina Dadoun, Christopher Rein, Christophe Hudry, Sarah Kreis, Bruno Fautrel, Edouard Pertuiset, Laure Gossec
Physical activity is recommended in axial spondyloarthritis (axSpA) but may be insufficiently performed. The objective of this study was to assess physical activity in axial spondyloarthritis and to explore its explanatory factors. This was a cross-sectional study of patients with definite axSpA. The level of physical activity (International Physical Activity Questionnaire-Long form, IPAQ-L), type of aerobic exercise and the Exercise Benefits and Barriers Score were collected. Multivariate logistic regression analyses were performed to explain levels of exercise at least as recommended by the World Health Organization...
September 24, 2016: Rheumatology International
Jean Wach, Marie-Claude Letroublon, Fabienne Coury, Jacques Guy Tebib
OBJECTIVE: Spondyloarthritis (SpA) is the second most frequent inflammatory rheumatic disease, characterized by spinal involvement, peripheral arthritis, or enthesitis with marked pain, stiffness, and fatigue. Fibromyalgia (FM) may be associated with SpA, and shares some common symptoms. We aimed to determine how FM influences assessment of SpA disease activity, which is mainly dependent on patient-based outcome measures such as the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) or the Ankylosing Spondylitis Disease Activity Score (ASDAS)...
September 15, 2016: Journal of Rheumatology
Qinghua Zou, Yi Jiang, Fangxiang Mu, Ying Shi, Yongfei Fang
BACKGROUND This study compared anxiety and depression in patients with nonradiographic axial spondyloarthritis (nr-axSpA) versus patients with ankylosing spondylitis (AS), and examined the relationship between clinical characteristics and psychological status. MATERIAL AND METHODS Patients diagnosed with axial spondyloarthritis (axSpA) were recruited for the study. Disease status was evaluated by the bath ankylosing spondylitis disease activity index (BASDAI), the bath ankylosing spondylitis functional index, visual analog scale, and the level of inflammatory markers...
2016: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
M Lorenzin, A Ortolan, P Frallonardo, S Vio, C Lacognata, F Oliviero, L Punzi, R Ramonda
Our aim was to determine the prevalence of spine and sacroiliac joint (SIJ) lesions on magnetic resonance imaging (MRI) in patients with early axial spondyloarthritis (axSpA) and their correlation with disease activity indices. Sixty patients with low back pain (LBP) (≥3 months, ≤2 years, onset ≤45 years), attending the SpA-clinic of the Unità Operativa Complessa Reumatologia of Padova [SpondyloArthritis-Caught-Early (SPACE) study], were studied following a protocol including physical examination, questionnaires, laboratory tests, X-rays and spine and SIJ MRI...
2016: Reumatismo
L T Hermansen, A G Loft, A A Christiansen, H L Munk, L Gilbert, A G Jurik, B Arnbak, C Manniche, U Weber, M Østergaard, S J Pedersen, T Barington, P Junker, K Hørslev-Petersen, O Hendricks
OBJECTIVES: To investigate whether antibody response patterns against Klebsiella pneumoniae capsular serotypes can discriminate patients with axial spondyloarthritis (axSpA) from patients with non-specific low back pain (LBP). METHOD: Immunoglobulin (Ig)G and IgA antibodies against K. pneumoniae capsular serotypes K2, K26, K36, and K50 were measured, and antibody seropositivity compared between groups and analysed for patient correlation in five different groups: (a) 96 patients fulfilling the Assessment of SpondyloArthritis International Society (ASAS) classification criteria for axSpA; (b) 38 patients with either a positive magnetic resonance imaging (MRI) scan as defined by ASAS or a positive human leucocyte antigen (HLA)-B27 status plus one clinical SpA feature, characterized as 'non-axSpA'; (c) 82 non-specific LBP patients; (d) 40 healthy blood donors and (e) 43 patients with diagnosed ankylosing spondylitis (AS) served as the negative and positive control groups...
September 7, 2016: Scandinavian Journal of Rheumatology
Yung-Feng Yen, Pei-Hung Chuang, I-An Jen, Marcelo Chen, Yu-Ching Lan, Yen-Ling Liu, Yun Lee, Yen-Hsu Chen, Yi-Ming Arthur Chen
OBJECTIVES: It is not known if the incidences of autoimmune diseases are higher in individuals living with HIV infection or AIDS. Our study investigated the incidences of autoimmune diseases among people living with HIV/AIDS (PLWHA) in Taiwan during 2000-2012. METHODS: The Taiwan National Health Insurance Research Database was used to identify PLWHA. The incidence densities of systemic and organ-specific autoimmune diseases were calculated, and age-adjusted, sex-adjusted and period-adjusted standardised incidence rates (SIRs) were obtained by using two million people from the general population as controls...
September 2, 2016: Annals of the Rheumatic Diseases
Kevin L Winthrop, Vibeke Strand, Désiréé M van der Heijde, Philip J Mease, Mary K Crow, Michael Weinblatt, Joan M Bathon, Maya H Buch, Gerd R Burmester, Maxime Dougados, Jonathan Kay, Xavier Mariette, Ferry C Breedveld, Joachim R Kalden, Josef S Smolen, Daniel E Furst
The 18th annual international Targeted Therapies meeting brought together over 100 leading scientists and clinicians from around the world in the field of rheumatology. During the meeting, breakout sessions were held consisting of 5 disease-specific groups each with 20-40 experts assigned to each group based on clinical or scientific expertise. Specific groups included: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis/spondyloarthritis, systemic lupus erythematous, and other connective tissue diseases (e...
July 2016: Clinical and Experimental Rheumatology
Janneke J de Winter, Leonieke J van Mens, Désirée van der Heijde, Robert Landewé, Dominique L Baeten
BACKGROUND: Peripheral disease (arthritis, enthesitis and dactylitis) and extra-articular disease (uveitis, psoriasis and inflammatory bowel disease) is common in ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). So far, however, summary data on the prevalence are lacking. The objective of this meta-analysis was to assess the prevalence of peripheral and extra-articular manifestations in ankylosing spondylitis (AS) and nr-axSpA. METHODS: We performed a systematic literature search to identify publications describing the prevalence of peripheral and extra-articular disease manifestations in patients with AS and nr-axSpA...
September 1, 2016: Arthritis Research & Therapy
Joachim Sieper, Atul Deodhar, Helena Marzo-Ortega, Jacob A Aelion, Ricardo Blanco, Tseng Jui-Cheng, Mats Andersson, Brian Porter, Hanno B Richards
BACKGROUND: There is significant unmet need in patients with ankylosing spondylitis (AS) who have inadequate response or intolerance to anti-tumour necrosis factor (TNF) treatment. Secukinumab, an anti-interleukin-17A monoclonal antibody, significantly improved signs and symptoms of AS in the MEASURE 2 study (NCT01649375). METHODS: Subjects with active AS (N=219) received secukinumab (150 or 75 mg) or placebo at baseline, weeks 1, 2, 3 and 4, and every 4 weeks thereafter...
August 31, 2016: Annals of the Rheumatic Diseases
Jing Liu, Zheng Dong, Qi Zhu, Dongyi He, Yanyun Ma, Aiping Du, Fan He, Dongbao Zhao, Xia Xu, Hui Zhang, Li Jin, Jiucun Wang
While previous studies have researched in association analyses between TNFα promoter polymorphisms and responses to TNF blockers in spondyloarthritis patients, their results were conflicting. Therefore, we aimed to determine whether TNFα promoter polymorphisms could predict response to TNF blockers and find the source of heterogeneity. Data were extracted and analyzed from published articles and combined with our unpublished data. We found that the greatest potential sources of heterogeneity in the results were gender ratio, disease type, continents, and TNF blockers...
2016: Scientific Reports
Louise Hamilton, Nick Barkham, Ashok Bhalla, Robin Brittain, Debbie Cook, Gareth Jones, Kirsten Mackay, David Marshall, Helena Marzo-Ortega, Daniel Murphy, Claire Riddell, Raj Sengupta, Stefan Siebert, Liz Van Rossen, Karl Gaffney
No abstract text is available yet for this article.
August 24, 2016: Rheumatology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"